Remove Clinical Trials Remove DEA Remove Legalization Remove Policy
article thumbnail

NORML Formally Responds to DEA’s Proposed Changes to Marijuana Cultivation Rules

NORML

Under existing regulations, the agency only licenses one facility — the University of Mississippi — to cultivate cannabis for use in FDA-approved clinical trials. In 2016, the agency appeared to reconsider its longstanding policy, and publicly stated for the first time that it would consider additional applicants.

article thumbnail

Justice Department Urged To Take “Immediate Action” On Marijuana Grow Applications

NORML

In August 2016, the US Drug Enforcement Administration announced in the US Federal Register that the agency was “adopting a new policy that is designed to increase the number of entities registered under the Controlled Substances Act to grow (manufacture) marijuana to supply legitimate researchers in the United States.”

DEA 188
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Ketamine Clinic Craze: Legalities and Possibilities

Canna Law Blog

Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). This post is dedicated to clearing up some of the confusion behind ketamine clinic set-up and operation.

Therapy 104
article thumbnail

Psilocybin-Alcohol Study, FDA’s Psychedelic Guide, & the NCAA’s Cannabis Overhaul Begins

Veriheal

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

article thumbnail

Veterans Try Cannabis To Treat PTSD

SpeedWeed

CANNABIS CULTURE – The results are now in after the first-ever legal clinical trial into the use of cannabis to treat PTSD, but did the DEA’s rules taint the outcome? Seventy-six mostly male veterans between the ages of 24 and 77 completed the Phase 1 trial.

article thumbnail

Emerge Law Group (OR): PSILOCYBIN THERAPY FOR PATIENTS WITH ADVANCED ILLNESS IN OREGON

Cannabis Law Report

A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. However, this drug is not presently legally available, as it is classified as a Schedule I drug, severely restricted and regulated by the federal Controlled Substances Act.

Therapy 52
article thumbnail

MAPS Is 36 Years Old – Doblin Provides Precis Timeline of the Organization

Cannabis Law Report

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. Now, we are closer than ever to legalizing MDMA-assisted therapy for posttraumatic stress disorder (PTSD), though there is still a long road ahead. Rick Doblin, Ph.D., Rick Doblin, Ph.D.,